Atara to Extend Phase 1 Trial of Potential Immunotherapy for All MS Forms to US Patients – Multiple Sclerosis News Today
Multiple Sclerosis News Today |
Atara to Extend Phase 1 Trial of Potential Immunotherapy for All MS Forms to US Patients
Multiple Sclerosis News Today ATA188 is a T-cell immunotherapy that targets immune B-cells and plasma cells in the brain and spinal cord that have been infected with the Epstein-Barr virus (EBV). A considerable body of research links EBV infection with the autoimmune processes in … Atara Biotherapeutics Announces FDA Clearance To Proceed With Enrollment At US Sites For Ongoing Global Phase … |
